Comments
Lupin has received approval from the US health regulator to market Decitabine for Injection, used for the treatment of myelodysplastic syndrome. The company has received approval from the United States Food and Drug Administration to market Decitabine for Injection, 50 mg/vial, single-dose vial, Lupin said in a statement.
Decitabine -- the generic version of Otsuka’s Dacogen for Injection, 50 mg/vial -- had annual sales of approximately $135.9 million in the US. Shares of Lupin were trading at Rs 852.00 apiece on the BSE, up 1.27 per cent, from their previous close.
Comments
COMMENT NOW
Comments
Comments have to be in English, and in full sentences. They cannot be abusive or personal. Please abide by our community guidelines for posting your comments.
We have migrated to a new commenting platform. If you are already a registered user of TheHindu Businessline and logged in, you may continue to engage with our articles. If you do not have an account please register and login to post comments. Users can access their older comments by logging into their accounts on Vuukle.